Senior Vice President, Biotherapeutics

Ankita Srivastava brings deep experience in advancing innovative biologics and small-molecule therapeutics from early discovery through clinical development, with leadership roles at AlivaMab Biologics, Ichnos Glenmark Innovation, Denali Therapeutics, and Takeda Pharmaceuticals. Her work has contributed to multiple clinical-stage programs including the trispecific ISB 2001 (now partnered with AbbVie) and Denali’s BBB-penetrant biologics platform (DNL310, DNL593/TAK-594).

Earlier in her career, Ankita led Protein sciences lab at a biotech incubator within Cedars-Sinai’s IBD department, later acquired by Prometheus Biosciences and Merck. She has extensive experience developing novel antibody discovery platforms and building high-performing teams focused on next-generation modalities.

Ankita earned her Ph.D. in GPCR structural biology from the Max Planck Institute for Biophysics and completed postdoctoral training at Stanford. She holds an M.S. in Biotechnology and a B.S. in Chemistry and Botany from India.